Bristol-Myers Squibb Aktie News

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026.

One is a sector mainstay that has now raised its payout 17 years in a row. The other is a big player in the animal healthcare space.

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Trump, according to sources familiar with the situation.

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-genera...

These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue.

Chevron is an integrated energy company with an impressive yield and an impressive dividend history. Bristol Myers has a high yield, but the drugmaker is out of favor.

This article presents a diversified, fund-based portfolio targeting market-matching growth and a 6%+ income yield, with lower tech exposure than the S&P 500. The model portfolio, comprising 5 ETFs and 6 CEFs, emphasizes asset class diversification—spanning blue-chip dividends, tech, real estate, gold, materials, energy, and utilities. The portfolio presented uses ahands-off approach, and it is ...

Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript